Search

Your search keyword '"Van Den Weyngaert D"' showing total 188 results
Start Over Author "Van Den Weyngaert D"
188 results on '"Van Den Weyngaert D"'

5. Abstract P6-19-01: Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

Author

Bayani, J, primary, Poncet, C, additional, Yao, CQ, additional, Crozier, C, additional, Anouk, N, additional, Piper, T, additional, Cunningham, C, additional, Sobol, M, additional, Aebi, S, additional, Benstead, K, additional, Bogler, O, additional, Dal Lago, L, additional, Fraser, J, additional, Hilbers, FH, additional, Hedenfalk, I, additional, Korde, L, additional, Linderholm, B, additional, Martens, J, additional, Middleton, L, additional, Murray, M, additional, Kelly, C, additional, Nilsson, C, additional, Nowaczyk, M, additional, Peeters, S, additional, Peric, A, additional, Porter, P, additional, Schröder, C, additional, Rubio, IT, additional, Ruddy, KJ, additional, van Asperen, C, additional, Van Den Weyngaert, D, additional, van Deurzen, C, additional, van Leeuwen-Stok, E, additional, Vermeij, J, additional, Winer, E, additional, Boutros, PC, additional, Giordano, SH, additional, Cardoso, F, additional, and Bartlett, JM, additional

Published
2019
Full Text
View/download PDF

6. Abstract PD7-12: Molecular subtyping of male breast cancer by the International male breast cancer program (IMBC): EORTC 10085/TBCRC 0-29/BIG 2-07/NABCG/BOOG 2009-04

Author

Martens, JWM, primary, Sieuwerts, A, additional, Ponchet, C, additional, Smid, M, additional, de Weerd, V, additional, Slaets, L, additional, Piper, T, additional, van Deurzen, CHM, additional, Schroder, CP, additional, Stangle, C, additional, Kloosterman, W, additional, van Leeuwen-Stok, E, additional, Nilsson, C, additional, Vermeij, J, additional, Peeters, S, additional, Goulioti, T, additional, Nowaczyk, M, additional, Aebi, S, additional, Rubio, IT, additional, Kelly, C, additional, Bayani, J, additional, Porter, P, additional, Murray, M, additional, Hudis, C, additional, Middleton, L, additional, Korde, L, additional, Ruddy, K, additional, Winer, E, additional, Bogler, O, additional, van den Weyngaert, D, additional, dal Lago, L, additional, Fraser, J, additional, Benstead, K, additional, van Asperen, C, additional, Linderholm, B, additional, Hedenfalk, I, additional, Tryfonidis, K, additional, Giordano, S, additional, Bartlett, J, additional, and Cardoso, F, additional

Published
2018
Full Text
View/download PDF

7. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Author

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, Van Den Weyngaert D, Kaendler S, Krauseneck P, Vinolas N, Villa S, Wurm RE, Maillot MHB, Spagnolli F, Kantor G, Malhaire JP, Renard L, De Witte O, Scandolaro L, Vecht CJ, Maingon P, Lutterbach J, Kobierska A, Bolla M, Souchon R, Mitine C, Tzuk-Shina T, Kuten A, Haferkamp G, de Greve J, Priou F, Menten J, Rutten I, Clavere P, Malmstrom A, Jancar B, Newlands E, Pigott K, Twijnstra A, Chinot O, Reni M, Boiardi A, Fabbro M, Campone M, Bozzino J, Frenay M, Gijtenbeek J, Delattre JY, De Paula U, Hanzen C, Pavanato G, Schraub S, Pfeffer R, Soffietti R, Kortmann RD, Taphoorn M, Torrecilla JL, Grisold W, Huget P, Forsyth P, Fulton D, Kirby S, Wong R, Fenton D, Cairncross G, Whitlock P, Burdette-Radoux S, Gertler S, Saunders S, Laing K, Siddiqui J, Martin LA, Gulavita S, Perry J, Mason W, Thiessen B, Pai H, Alam ZY, Eisenstat D, Mingrone W, Hofer S, Pesce G, Dietrich PY, Thum P, Baumert B, Ryan G, Stupp, R, Mason, Wp, van den Bent, Mj, Weller, M, Fisher, B, Taphoorn, Mjb, Belanger, K, Brandes, Aa, Marosi, C, Bogdahn, U, Curschmann, J, Janzer, Rc, Ludwin, Sk, Gorlia, T, Allgeier, A, Lacombe, D, Cairncross, Jg, Eisenhauer, E, Mirimanoff, Ro, Van Den Weyngaert, D, Kaendler, S, Krauseneck, P, Vinolas, N, Villa, S, Wurm, Re, Maillot, Mhb, Spagnolli, F, Kantor, G, Malhaire, Jp, Renard, L, De Witte, O, Scandolaro, L, Vecht, Cj, Maingon, P, Lutterbach, J, Kobierska, A, Bolla, M, Souchon, R, Mitine, C, Tzuk-Shina, T, Kuten, A, Haferkamp, G, de Greve, J, Priou, F, Menten, J, Rutten, I, Clavere, P, Malmstrom, A, Jancar, B, Newlands, E, Pigott, K, Twijnstra, A, Chinot, O, Reni, M, Boiardi, A, Fabbro, M, Campone, M, Bozzino, J, Frenay, M, Gijtenbeek, J, Delattre, Jy, De Paula, U, Hanzen, C, Pavanato, G, Schraub, S, Pfeffer, R, Soffietti, R, Kortmann, Rd, Taphoorn, M, Torrecilla, Jl, Grisold, W, Huget, P, Forsyth, P, Fulton, D, Kirby, S, Wong, R, Fenton, D, Cairncross, G, Whitlock, P, Burdette-Radoux, S, Gertler, S, Saunders, S, Laing, K, Siddiqui, J, Martin, La, Gulavita, S, Perry, J, Mason, W, Thiessen, B, Pai, H, Alam, Zy, Eisenstat, D, Mingrone, W, Hofer, S, Pesce, G, Dietrich, Py, Thum, P, Baumert, B, Ryan, G, Neurology, and Plastic and Reconstructive Surgery and Hand Surgery

Subjects
Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Adrenal Cortex Hormones, Adrenal Cortex Hormones/therapeutic use Adult Aged Antineoplastic Agents, Alkylating/adverse effects/*therapeutic use Brain Neoplasms/*drug therapy/mortality/*radiotherapy Chemotherapy, Adjuvant Dacarbazine/adverse effects/*analogs & derivatives/*therapeutic use Disease Progression Female Glioblastoma/*drug therapy/mortality/*radiotherapy Humans Male Middle Aged Proportional Hazards Models Radiotherapy, Computer-Assisted/adverse effects Survival Analysis, medicine, Temozolomide, Humans, Survival rate, Pseudoprogression, Antineoplastic Agents, Alkylating, Aged, Proportional Hazards Models, business.industry, Brain Neoplasms, Hazard ratio, General Medicine, Middle Aged, Debulking, medicine.disease, Survival Analysis, Radiotherapy, Computer-Assisted, Surgery, Radiation therapy, Dacarbazine, Chemotherapy, Adjuvant, Concomitant, Disease Progression, Female, business, Glioblastoma, medicine.drug, Anaplastic astrocytoma
Abstract

BACKGROUND: Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy. In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety. METHODS: Patients with newly diagnosed, histologically confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle). The primary end point was overall survival. RESULTS: A total of 573 patients from 85 centers underwent randomization. The median age was 56 years, and 84 percent of patients had undergone debulking surgery. At a median follow-up of 28 months, the median survival was 14.6 months with radiotherapy plus temozolomide and 12.1 months with radiotherapy alone. The unadjusted hazard ratio for death in the radiotherapy-plus-temozolomide group was 0.63 (95 percent confidence interval, 0.52 to 0.75; P

Published
2005
Full Text
View/download PDF

11. Alanine/EPR dosimetry applied to the verification of a total body irradiation protocol and treatment planning dose calculation using a humanoid phantom

Author

Schaeken, B., Lelie, Steven, Meijnders, P, Van Den Weyngaert, D, Janssens, Herwig, Verellen, Dirk, Medical Imaging and Physical Sciences, and Materials and Chemistry

Abstract

Purpose: To avoid complications in total body irradiation (TBI), it is important to achieve a homogeneous dose distribution throughout the body and to deliver a correct dose to the lung which is an organ at risk. The purpose of this work was to validate the TBI dose protocol and to check the accuracy of the 3D dose calculations of the treatment planning system. Methods: Dosimetry based on alanine/electron paramagnetic resonance (EPR) was used to measure dose at numerous locations within an anthropomorphic phantom (Alderson®) that was irradiated in a clinical TBI beam setup. The alanine EPR dosimetry system was calibrated against water calorimetry in a Co-60 beam and the absorbed dose was determined by the use of “dose-normalized amplitudes”math formula. The dose rate of the TBI beam was checked against a Farmer ionization chamber. The phantom measurements were compared to 3D dose calculations from a treatment planning system (Pinnacle®) modeled for standard dose calculations. Results: Alanine dosimetry allowed accurate measurements which were in accordance with ionization chamber measurements. The combined relative standard measurement uncertainty in the Alderson phantom wasmath formula. The humanoid phantom was irradiated to a reference dose of 10 Gy, limiting the lung dose to 7.5 Gy. The ratio of the average measured dose midplane in the craniocaudal direction to the reference dose was 1.001 with a spread of ±4.7% (1 sd). Dose to the lung was measured in 26 locations and found, in average, 1.8% lower than expected. Lung dose was homogeneous in the ventral-dorsal direction but a dose gradient of math formula was observed in the craniocaudal direction midline within the lung lobe. 3D dose calculations (Pinnacle®) were found, in average, 2% lower compared to dose measurements on the body axis and 3% lower for the lungs. Conclusions: The alanine/EPR dosimetry system allowed accurate dose measurements which enabled the authors to validate their TBI dose protocol. Dose calculations based on a collapsedcone convolution dose algorithm modeled for regular treatments are accurate within 3% and can further be improved when the algorithm is modeled for TBI.

Published
2010

17. RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service de radiothérapie oncologique, Van Gestel, D., van Vliet-Vroegindeweij, C., Van den Heuvel, F., Crijns, W., Coelmont, A., De Ost, B., Holt, A., Lamers, E., Geussens, Y., Nuyts, S., Van den Weyngaert, D., Van den Wyngaert, T., Vermorken, J.B., Gregoire, Vincent, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service de radiothérapie oncologique, Van Gestel, D., van Vliet-Vroegindeweij, C., Van den Heuvel, F., Crijns, W., Coelmont, A., De Ost, B., Holt, A., Lamers, E., Geussens, Y., Nuyts, S., Van den Weyngaert, D., Van den Wyngaert, T., Vermorken, J.B., and Gregoire, Vincent

Abstract

Backround: Radiotherapy techniques have evolved rapidly over the last decade with the introduction of Intensity Modulated RadioTherapy (IMRT) in different forms. It is not clear which of the IMRT techniques is superior in the treatment of head and neck cancer patients in terms of coverage of the planning target volumes (PTVs), sparing the organs at risk (OARs), dose to the normal tissue, number of monitor units needed and delivery time. The present paper aims to compare Step and Shoot (SS) IMRT, Sliding Window (SW) IMRT, RapidArc (RA) planned with Eclipse, Elekta VMAT planned with SmartArc (SA) and helical TomoHDTM (HT). Methods: Target volumes and organs at risk (OARs) of five patients with oropharyngeal cancer were delineated on contrast enhanced CT-scans, then treatment plans were generated on five different IMRT systems. In 32 fractions, 69.12 Gy and 56 Gy were planned to the therapeutic and prophylactic PTVs, respectively. For the PTVs and 26 OARs ICRU 83 reporting guidelines were followed. Differences in the studied parameters between treatment planning systems were analysed using repeated measures ANOVA. Results: Mean Homogeneity Index of PTVtherapeutic is better with HT(.06) followed by SA(.08), RA(.10), SW(.10) and SS(.11). PTVprophylactic is most homogeneous with RA. Parotid glands prescribed mean doses are only obtained by SA and HT, 20.6 Gy and 21.7 Gy for the contralateral and 25.6 Gy and 24.1 Gy for the ipsilateral, against 25.6 Gy and 32.0 Gy for RA, 26.4 Gy and 34.6 Gy for SW, and 28.2 Gy and 34.0 Gy for SS. RA uses the least monitor units, HT the most. Treatment times are 3.05 min for RA, and 5.9 min for SA and HT. Conclusions: In the treatment of oropharyngeal cancer, we consider rotational IMRT techniques preferable to fixed gantry techniques due to faster fraction delivery and better sparing of OARs without a higher integral dose. TomoHD gives most homogeneous target coverage with more sparing of spinal cord, brainstem, parotids and the lower swa

Published
2013

18. Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity

Author

UCL - (MGD) Service d'oncologie médicale, Nuyts, S., Lambrecht, M., Duprez, F., Daisne, Jean-François, Van Gestel, D., Van Den Weyngaert, D., Platteaux, N., Geussens, Y., Voordeckers, M., Madani, I., De Neve, W., UCL - (MGD) Service d'oncologie médicale, Nuyts, S., Lambrecht, M., Duprez, F., Daisne, Jean-François, Van Gestel, D., Van Den Weyngaert, D., Platteaux, N., Geussens, Y., Voordeckers, M., Madani, I., and De Neve, W.

Abstract

Background and purpose A randomized trial was initiated to investigate whether a reduction of the dose to the elective nodal sites and the swallowing apparatus delivered by IMRT would result in a reduction of acute and late side effects without compromising tumor control. The aim of this paper is to report on dosimetrical analysis and acute toxicity. Materials & methods Two-hundred patients were randomized. In the standard arm, elective nodal volumes (PTV elect) were irradiated up to an equivalent dose of 50 Gy. In the experimental arm an equivalent dose of 40 Gy was prescribed to the PTV elect. The dose to the swallowing apparatus was kept as low as possible without compromising therapeutic PTV (PTVther) coverage. Results No significant difference was seen between both arms concerning PTV ther coverage. The median D95 of the PTVelect was significantly lower in the experimental arm (39.5 vs 49.8 Gy; p < 0.001). Concerning the organs at risk, the dose to swallowing structures and spinal cord was significantly reduced. There was no significant difference in acute toxicity. Three months after radiotherapy there was significantly less grade ≥3 dysphagia in the experimental arm (2% vs 11%; p = 0.03). With a median follow-up of 6 months no significant differences were observed in locoregional control, disease free survival or overall survival. Conclusions Using IMRT we were able to significantly reduce the dose to the PTVelect and several organs at risk without compromising PTVther coverage. This resulted in a significant reduction of severe dysphagia 3 months after radiotherapy. Further follow-up is necessary to investigate whether these observations translate into a benefit on late treatment related dysphagia without affecting treatment outcome. © 2013 Elsevier Ireland Ltd. All rights reserved.

Published
2013

20. Reference dosimetry for helical tomotherapy: Practical implementation and a multicenter validation

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, De Ost, B., Schaeken, B., Vynckier, S., Sterpin, Edmond, Van den Weyngaert, D., UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, De Ost, B., Schaeken, B., Vynckier, S., Sterpin, Edmond, and Van den Weyngaert, D.

Abstract

Purpose: The aim of this study was to implement a protocol for reference dosimetry in tomotherapy and to validate the beam output measurements with an independent dosimetry system. Methods: Beam output was measured at the reference depth of 10 cm in water for the following three cases: (1) a 5 x 10 cm(2) static machine specific reference field (MSR), (2) a rotational 5 x 10 cm(2) field without modulation and no tabletop in the beam, (3) a plan class specific reference (PCSR) field defined as a rotational homogeneous dose delivery to a cylindrical shaped target volume: plan with modulation and table-top movement. The formalism for reference dosimetry of small and nonstandard fields [Med.Phys. 35: 5179-5186, 2008] and QA recommendations [Med.Phys. 37: 4817-4853, 2010] were adopted in the dose measurement protocol. All ionization chamber measurements were verified independently using alanine/EPR dosimetry. As a pilot study, the beam output was measured on tomotherapy Hi-art systems at three other centers and directly compared to the centers specifications and to alanine dosimetry. Results: For the four centers, the mean static output at a depth of 10 cm in water and SAD = 85 cm, measured with an A1SL chamber following the TG-148 report was 6.238 Gy/min +/- 0.058 (1 SD); the rotational output was 6.255 Gy/min +/- 0.069 (1 SD). The dose stated by the center was found in good agreement with the measurements of the visiting team: D(center)/D(visit) = 1.000 +/- 0.003 (1 SD). The A1SL chamber measurements were all in good agreement with Alanine/EPR dosimetry. Going from the static reference field to the rotational/non modulated field the dose rate remains constant within 0.2% except for one center where a deviation of 1.3% was detected. Conclusions: Following the TG-148 report, beam output measurements in water at the reference depth using a local protocol, as developed at different centers, was verified. The measurements were found in good agreement with alanine/EPR dosimet

Published
2011

21. Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience.

Author

Van Gestel, Dirk, Van Den Weyngaert, D, Schrijvers, D, Weyler, J, Vermorken, J B, Van Gestel, Dirk, Van Den Weyngaert, D, Schrijvers, D, Weyler, J, and Vermorken, J B

Abstract

The purpose of this study was to analyse retrospectively the intensity-modulated radiotherapy (IMRT) results in patients with head and neck cancer (HNC) treated between November 2003 and June 2007., info:eu-repo/semantics/published

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results